On September 27, 2023, Kiromic BioPharma, Inc. (the "Company") issued a 25% Senior Secured Convertible Promissory Note (the "Note") to an accredited investor (Filing, Kiromic, SEP 27, 2023, View Source [SID1234635599]). The Note has a principal amount of $2,400,000, bears interest at a rate of 25% per annum (the "Stated Rate") and matures on September 27, 2024 (the "Maturity Date"), on which the principal balance and accrued but unpaid interest under the Note shall be due and payable. The Stated Rate will increase to 27% per annum or the highest rate then allowed under applicable law (whichever is lower) upon occurrence of an event of default, including the failure by the Company to make payment of principal or interest due under the Note on the Maturity Date, and any commencement by the Company of a case under any applicable bankruptcy or insolvency laws.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Note is convertible into shares (the "Conversion Shares") of the Company’s common stock, par value $0.001 per share (the "Common Stock"), at an initial conversion price of $5.00 per share (the "Conversion Price"), subject to a beneficial ownership limitation equivalent to 9.99% (the "Beneficial Ownership Limitation").

The unpaid principal of and interest on the Note constitute unsubordinated obligations of the Company and are senior and preferred in right of payment to all subordinated indebtedness and equity securities of the Company outstanding as of the Issuance Date; provided, however, that the Company may incur or guarantee additional indebtedness after the Issuance Date, whether such indebtedness are senior, pari passu or junior to the obligations under the Note, which are secured by all of the Company’s right, title and interest, in and to, (i) all fixtures (as defined in the Uniform Commercial Code, the "UCC") and equipment (as defined in the UCC), and (ii) all of the Company’s intellectual property as specified in the Note, subject to certain exclusions as described in the Note.

The foregoing description of the Note is qualified in its entirety by reference to the full text of such Note, a copy of which is attached hereto as exhibit 10.1 and incorporated herein by reference.

On September 27, 2023 Accelerator Life Science Partners (ALSP), an early-stage life science accelerator and investment firm that creates and builds next-generation biotechnology companies centered on innovative science, reported the Series A financing of Automera, a new biotechnology company that focuses on the development of autophagy-targeting chimera small molecules (AUTACs) (Press release, Automera, SEP 27, 2023, View Source [SID1234635491]). Augmented with quantum chemistry and artificial intelligence (AI) enabled drug discovery tools, Automera’s AUTACs have the broad potential to rapidly generate novel therapeutic leads for a range of diseases. Automera will initially focus its product development efforts to treat cancer. The company was established by co-founders Associate Professor Michael Lazarou, Loong Wang, and Taiyang Zhang at Talo Labs Pte Ltd. in collaboration with ALSP. Automera has secured $16M in Series A funding, a co-led endeavor by ALSP and ClavystBio, with participation from Singapore-based global investor EDBI, Xora Innovation, and other undisclosed investors. Joining the Board of Directors are Loong Wang, from Automera, Dr. Alice Chen and Thong Q. Le, from ALSP, and Dr. Wen Qi Ho, from ClavystBio.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"ALSP has long been interested in helping to drive biopharma innovation emerging in Singapore," said Alice Chen, Executive Vice President at ALSP and Automera board member. "As our first investment in Singapore, Automera exemplifies the innovative scientific and translational research ongoing in the region. We plan to leverage ALSP’s unique company-building capabilities in Singapore, and we look forward to working with the broader Singapore community to enhance the platform technologies and early-stage therapeutic programs that Automera will develop. We are honored to co-lead Automera’s Series A financing with our partners at ClavystBio and are excited about expanding Automera’s operations in the months ahead."

Automera’s AUTAC platform is a next-generation approach to realizing the potential of targeted protein degradation (TPD) as a therapeutic modality. TPD, an emerging field of novel therapeutics, catalyzes the degradation of disease-related proteins while retaining the benefits of small molecules. Automera’s AUTAC platform is designed to generate novel therapies that degrade not only disease-related proteins but also protein aggregates, organelles, and pathogens. AUTACs have the potential to provide a more flexible approach to protein degradation than existing approaches such as proteolysis-targeting chimeras (PROTACs) to trigger protein degradation.

"Automera was founded on the premise that improving health outcomes for people with serious diseases requires new technologies that make it easier, faster, and less expensive to develop safe and effective medicines," said Loong Wang, co-founder of Automera. "We believe that our AUTAC platform is one such technology, with broad potential across multiple disease indications that are difficult to treat with current therapeutic approaches. We greatly value the business and financial support that ALSP provides and are proud that leading healthcare investors are participating in Automera’s Series A financing. With these resources, Automera is well positioned to deploy our AUTAC platform toward the development of potentially transformative therapies."

Automera has assembled a distinguished scientific advisory group that includes Associate Professor Michael Lazarou, Automera’s Scientific Co-Founder at the Walter and Eliza Hall Institute of Medical Research (WEHI) and the Monash Biomedicine Discovery Institute, Dr. Nicholas Ktistakis from Babraham Institute, Dr. Gene Yeo from the University of California San Diego (UCSD) and Dr. Kendall Mohler from ALSP.

"ClavystBio is excited to be building new ventures in Singapore through partnerships with young entrepreneurs like Loong Wang and his team at Automera, and smart capital investors like ALSP," said Wen Qi Ho, Therapeutics Lead at ClavystBio. "Our mission is to accelerate the commercialization of breakthrough innovations like the AUTAC platform for health impact, and we welcome Automera and ALSP to Singapore’s growing life sciences translational community."

On September 27, 2023 Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, reported presentations on POSLUMA (flotufolastat F 18) injection (formerly known as 18F-rhPSMA-7.3) at the upcoming American Society for Therapeutic Radiology and Oncology (ASTRO) 2023 Annual Meeting, to be held in San Diego, Calif., from October 1 to 4, 2023 (Press release, Blue Earth Diagnostics, SEP 27, 2023, View Source [SID1234635490]). POSLUMA is indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer with suspected metastasis who are candidates for initial definitive therapy or with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"PET imaging with POSLUMA reveals clinical information crucial to decision-making for men with prostate cancer, and we are excited to share further information with the radiation oncology community at ASTRO 2023," said David E. Gauden, D.Phil., Chief Executive Officer of Blue Earth Diagnostics. "Phase 3 results from the SPOTLIGHT trial demonstrated the ability of POSLUMA to detect recurrent disease even at low prostate specific antigen (PSA) levels, and Dr. Ashesh Jani’s oral presentation will detail further information about its diagnostic performance at PSA levels <1 ng/mL. Dr. Phillip Kuo will present additional results from the Phase 3 LIGHTHOUSE trial that evaluated POSLUMA performance in newly diagnosed patients having high/very high risk prostate cancer and negative results with conventional imaging. Blue Earth Diagnostics will also host an Industry-Expert Theater event, ‘POSLUMA: Precision PET Imaging that is Truly Revealing’."

Details of selected oral and poster presentations by Blue Earth Diagnostics and its collaborators are listed below.

HIGHLIGHTED SCIENTIFIC PRESENTATIONS

Monday, October 2, 2023

Oral presentation

Title:

Detection Rate of 18F-rhPSMA-7.3 PET in Patients with Suspected Prostate Cancer Recurrence at PSA Levels <1 ng/mL: Data from the Phase 3 SPOTLIGHT Study

Presenter:

Ashesh B. Jani, MD, FASTRO, Department of Radiation Oncology, Winship Cancer Institute of Emory University, Atlanta, Ga., for the SPOTLIGHT Study Group

Session Type:

Oral

Session Title:

SS11 – GU 3 Novel Prognostication Techniques for Prostate Cancer

Presentation Time:

3:30 – 3:37 PM PT

Location:

Room 6 D/E

Presentation No.:

160

Tuesday, October 3, 2023

Poster presentation

Title:

Diagnostic Performance of 18F-rhPSMA-7.3 PET in Men with Newly Diagnosed High-risk Prostate Cancer and Negative Conventional Imaging

Presenter:

Phillip H. Kuo, MD, Ph.D., Departments of Medical Imaging, Medicine, and Biomedical Engineering, University of Arizona, Tucson, Ariz., on behalf of Gary A. Ulaner, MD, Ph.D., Hoag Family Cancer Institute, Irvine, Calif. and University of Southern California, Los Angeles, Calif., for the LIGHTHOUSE Study Group

Session Title:

PQ 06 – Poster Q&A 06 – Session 06 – Genitourinary Cancer, Patient Safety and Nursing

Presentation Time:

2:30 – 3:45 PM PT

Location:

Hall B1

Presentation No.:

2972

Blue Earth Diagnostics invites participants at the 2023 ASTRO Annual Meeting to attend the presentations above and visit the company at Exhibit Booth 2223. Blue Earth Diagnostics is hosting an Industry-Expert Theater event, "POSLUMA: Precision PET Imaging that is Truly Revealing," with invited speaker Dr. Nicholas Zouain, Radiation Oncologist, Medical Director of West Florida Radiation Therapy, US Oncology Network, Clearwater, Fla. The event will be held on Sunday, October 1, 2023, from 12:00 PM to 1:00 PM PT, in Theater 1 of the San Diego Convention Center. For full session details and scientific presentation listings, please see the ASTRO online program here.

Indication and Important Safety Information About POSLUMA

INDICATION
POSLUMA (flotufolastat F 18) injection is indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer

with suspected metastasis who are candidates for initial definitive therapy
with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level
IMPORTANT SAFETY INFORMATION

Image interpretation errors can occur with POSLUMA PET. A negative image does not rule out the presence of prostate cancer and a positive image does not confirm the presence of prostate cancer. The performance of POSLUMA for imaging metastatic pelvic lymph nodes in patients prior to initial definitive therapy seems to be affected by serum PSA levels and risk grouping. The performance of POSLUMA for imaging patients with biochemical evidence of recurrence of prostate cancer seems to be affected by serum PSA levels. Flotufolastat F 18 uptake is not specific for prostate cancer and may occur in other types of cancer, in non-malignant processes, and in normal tissues. Clinical correlation, which may include histopathological evaluation, is recommended.
Risk of Image Misinterpretation in Patients with Suspected Prostate Cancer Recurrence: The interpretation of POSLUMA PET may differ depending on imaging readers, particularly in the prostate/prostate bed region. Because of the associated risk of false positive interpretation, consider multidisciplinary consultation and histopathological confirmation when clinical decision-making hinges on flotufolastat F 18 uptake only in the prostate/prostate bed region or only on uptake interpreted as borderline.
POSLUMA use contributes to a patient’s overall long-term cumulative radiation exposure. Long-term cumulative radiation exposure is associated with an increased risk for cancer. Advise patients to hydrate before and after administration and to void frequently after administration. Ensure safe handling to minimize radiation exposure to the patient and health care providers.
The adverse reactions reported in ≥0.4% of patients in clinical studies were diarrhea, blood pressure increase and injection site pain.
Drug Interactions: androgen deprivation therapy (ADT) and other therapies targeting the androgen pathway, such as androgen receptor antagonists, may result in changes in uptake of flotufolastat F 18 in prostate cancer. The effect of these therapies on performance of POSLUMA PET has not been established.
To report suspected adverse reactions to POSLUMA, call 1-844-POSLUMA (1-844-767-5862) or contact FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Full POSLUMA prescribing information is available at www.posluma.com/prescribing-information.pdf.

On September 27, 2023 Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, reported the acceptance of three abstracts for a poster presentation at the upcoming Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 38th Annual Meeting to be held in San Diego, CA from November 1-5, 2023 (Press release, Adicet Bio, SEP 27, 2023, View Source [SID1234635489]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details of the poster presentation are as follows:

Abstract Title: Assay Development and Quantitative Detection of ADI-001, a CD20-Targeted γδ1 CAR T Therapy, using AlloCell, a Universal Assay for Monitoring of "Off-the-Shelf" Allogeneic Cell Therapies
Poster/Abstract Number: 684
Presenting Authors: Jackie Wilde, MS & Monica Moreno, PhD
Date/Time: November 4, 2023, from 9:00 a.m. – 8:30 p.m. PDT

Abstract Title: ADI-925: An Allogeneic "Off-the-Shelf" Chimeric Adapter (CAd) γδ T Cell Therapy Targeting NKG2D Ligand-Expressing Cancers
Poster/Abstract Number: 265
Presenting Authors: Marissa Herrman, PhD
Date/Time: November 3, 2023, from 9:00 a.m. – 8:30 p.m. PDT

Abstract Title: Disruption of the Cytokine Signaling Checkpoint CIS Enhances Serial-Killing and Anti-Tumor Activity of CAR-Engineered γδ T Cells
Poster/Abstract Number: 246
Presenting Authors: Beibei Ding, PhD
Date/Time: November 4, 2023, from 9:00 a.m. – 8:30 p.m. PDT

These abstracts will be available as a supplement in the Journal for ImmunoTherapy of Cancer (JITC) on Tuesday, October 31, 2023 at 9:00 a.m. EDT on www.sitcancer.org.

On September 27, 2023 AbCellera (Nasdaq: ABCL) reported two upcoming poster presentations on its T-cell engager platform at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 38th Annual Meeting, to be held virtually and at the San Diego Convention Center from November 1 to 5, 2023 (Press release, AbCellera, SEP 27, 2023, View Source [SID1234635488]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We have made significant progress on the application of our T-cell engager platform since we presented data at SITC (Free SITC Whitepaper) in 2022," said Bo Barnhart, Ph.D., VP, Translational Research at AbCellera. "We’re looking forward to presenting two posters this year demonstrating how key insights into CD3 T-cell engager biology help us to execute on our programs for various tumor targets, including a challenging peptide-MHC target."

Details on AbCellera’s poster presentations at SITC (Free SITC Whitepaper) are as follows:

Title: A rational approach for selecting CD3-binding antibodies for T-cell engager development
Abstract Number: 1367
Date and Time: Friday, November 3 from 9:00 a.m. to 7:00 p.m. PDT
Location: San Diego Convention Center, Exhibit Halls A and B1 or online at View Source

Title: Targeting intracellular tumor antigens to fight cancer: Discovery and development of functional and specific T-cell engagers against a MAGE-A4 pMHC
Abstract Number: 1395
Date and Time: Friday, November 3 from 9:00 a.m. to 7:00 p.m. PDT
Location: San Diego Convention Center, Exhibit Halls A and B1 or online at View Source

About T-Cell Engagers

CD3 T-cell engagers are bispecific antibodies that guide the immune system to find and eliminate cancer cells by binding both cancer-killing T cells and tumor targets at the same time. Developing effective T-cell engagers requires two parental antibodies—a CD3-binding arm that fine-tunes T-cell activation and a tumor-binding arm with high specificity for cancer cells. The small number of available CD3-binding antibodies that can effectively fine-tune T-cell responses has been a barrier to T-cell engager development. To address this barrier, AbCellera developed a complete T-cell engager platform that includes fully human, developable CD3-binding antibodies with unique binding and functional properties. By combining these antibodies with OrthoMabTM, its clinically validated multispecific engineering platform, and its antibody discovery and development engine, AbCellera’s T-cell engager platform is designed to bring new cancer medicines to the clinic faster.